SETDB1 and hepatocellular carcinoma: These findings highlight SETDB1 as an attractive biomarker and therapeutic target, and they lay the groundwork for future mechanistic studies and translational efforts aimed at incorporating SETDB1-directed strategies into precision medicine for HCC.